Plasma half-lives and bioavailability of human monoclonal Rh D antibodies BRAD-3 and BRAD-5 following intramuscular injection into Rh D-negative volunteers

Jean Goodrick(Bristol Institute for Transfusion Sciences), D J Anstee(NHS Blood and Transplant), Ben Dawes, Belinda M. Kumpel(NHS Blood and Transplant), G.E. Chapman(Bio Products Laboratory (United Kingdom)), DH Pamphilon(Bristol Institute for Transfusion Sciences), Iain D. C. Fraser(California Institute of Technology)
Clinical & Experimental Immunology
October 1, 1994
10.1111/j.1365-2249.1994.tb06600.x
Cited by 44

Related Papers

A novel lipid-anchored A-kinase Anchoring Protein facilitates cAMP-responsive membrane events
|The EMBO Journal|1998|285
Inflammatory monocytes regulate pathologic responses to commensals during acute gastrointestinal infection
|Nature Medicine|2013|266
A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy
|Blood|2013|226
Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity.
|PubMed|1994|107
Mechanism of anti-D-mediated immune suppression – a paradox awaiting resolution?
|Trends in Immunology|2001|103